G
Garret Hampton
Researcher at Genentech
Publications - 20
Citations - 1265
Garret Hampton is an academic researcher from Genentech. The author has contributed to research in topics: Cancer & Atezolizumab. The author has an hindex of 16, co-authored 20 publications receiving 1035 citations.
Papers
More filters
Journal ArticleDOI
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M. Spoerke,Steven Gendreau,Kimberly Walter,Jiaheng Qiu,Timothy R. Wilson,Heidi Savage,Junko Aimi,Mika K. Derynck,Meng Chen,Iris T. Chan,Lukas C. Amler,Garret Hampton,Stephen T. Johnston,Ian E. Krop,Peter Schmid,Mark R. Lackner +15 more
TL;DR: ESR1 mutation allele frequency does not show a consistent pattern of increases during fulvestrant treatment, and progression-free survival is not different in patients with ESR1 mutations compared with wild-type patients.
Journal ArticleDOI
Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
Jill M. Spoerke,Carol O'Brien,Ling Huw,Hartmut Koeppen,Jane Fridlyand,Rainer K. Brachmann,Peter M. Haverty,Ajay Pandita,Sankar Mohan,Deepak Sampath,Lori Friedman,Leanne Ross,Garret Hampton,Lukas C. Amler,David S. Shames,Mark R. Lackner +15 more
TL;DR: Candidate biomarkers for PI3K inhibitors have predictive value in preclinical models and show histology-specific alterations in primary tumors, suggesting that distinct biomarker strategies may be required in squamous compared with nonsquamous NSCLC patient populations.
Journal ArticleDOI
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
Marcin Kowanetz,Wei Zou,Scott N. Gettinger,Hartmut Koeppen,Mark M. Kockx,Peter Schmid,Edward E. Kadel,Ignacio I. Wistuba,Jamie E. Chaft,Naiyer A. Rizvi,David R. Spigel,Alexander I. Spira,Fred R. Hirsch,Victor Cohen,Dustin Smith,Zach Boyd,Natasha Miley,Susan Flynn,Vincent Leveque,David S. Shames,Marcus Ballinger,Simonetta Mocci,Geetha Shankar,Roel Funke,Garret Hampton,Alan Sandler,Lukas C. Amler,Ira Mellman,Daniel S. Chen,Priti S. Hegde +29 more
TL;DR: PD-L1 expression on TC or IC can independently attenuate anticancer immunity and emphasizes the functional importance of IC in regulating the antitumor T cell response.
Journal ArticleDOI
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.
Marie-Claire Wagle,Daniel C. Kirouac,Christiaan Klijn,Bonnie Liu,Shilpi Mahajan,Melissa R. Junttila,John Moffat,Mark Merchant,Ling Huw,Matthew Wongchenko,Kwame Okrah,Shrividhya Srinivasan,Zineb Mounir,Teiko Sumiyoshi,Peter M. Haverty,Robert L. Yauch,Yibing Yan,Omar Kabbarah,Garret Hampton,Lukas C. Amler,Saroja Ramanujan,Mark R. Lackner,Shih-Min A. Huang,Shih-Min A. Huang +23 more
TL;DR: An index that aggregates expression levels of 10 genes involved in modulating the mitogen-activated protein kinase (MAPK) pathway performed as well or better than other more complicated, genome-based tools at predicting whether drugs that inhibit MAPK-related enzymes were active against tumor cell lines.
Journal ArticleDOI
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
Marcin Kowanetz,Wei Zou,David S. Shames,Craig Cummings,Naiyer A. Rizvi,Alexander I. Spira,Garrett M. Frampton,Vincent Leveque,Susan Flynn,Simonetta Mocci,Geetha Shankar,Roel Funke,Marcus Ballinger,Daniel Waterkamp,Daniel S. Chen,Alan Sandler,Garret Hampton,Lukas C. Amler,Priti S. Hegde,Matthew D. Hellmann +19 more